The respiratory syncytial virus (RSV) causes acute bronchiolitis ... respiratory tract most commonly found among newborns. [1,2] The annual incidence of AB in newborns is 10% [3] with an admission ...

and coronaviruses (including SARS-CoV-2). Thus, incidence data for both hMPV and RSV are readily available, at least in hospitalised patient populations. Kulkarni and colleagues 3 performed various ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental A trio of respiratory illnesses — flu, COVID-19 and RSV — is sweeping the U.S. and leaving a trail of coughing and aching ...

Influenza, COVID-19, RSV and norovirus are all circulating at high levels in the U.S. Officials say the norovirus is especially nasty and a new strain to which there's little immunity. There are ...

An expert has urged people to be on the lookout for an extremely rare British coin created this week that is already selling for £250. While this coin is not currently in circulation, it could ...

People do not develop life-long immunity to the RSV virus. This means they can be infected many times. Bronchiolitis is common during the first 2 years of life. Most children just have coughing and ...

For 2025, its yield is a healthy-if-unspectacular 2.8%. Yet I believe the defence giant remains a top-tier dividend stock to consider. As the chart shows, the dividend on BAE Systems shares has ...

Today Early in the fall, experts might also see more cases of respiratory syncytial virus, Dr. Geeta Sood ... describes the results from the PURPOSE 1 and PURPOSE 2 trials as "a thrilling game changer ...

the infection leads to approximately 2.1 million outpatient visits and 58,000 hospitalisations each year. The scale of infections has led to predictions of very high sales for the first RSV ...

Of all vaccinees, 69.2% received Abrysvo, and 29.9% received Arexvy. "In June, 2023, the Advisory Committee on Immunization Practices recommended a single dose of RSV vaccine in adults aged 60 years ...

would provide continuous protection across multiple RSV seasons. First data from a phase 1/2 trial shows placebo-like tolerability and a 93% antibody response with two doses, according to Sanofi.